Miguel Martín

Neoadjuvant Abemaciclib plus Letrozole Versus Chemotherapy in Patients with HR+/HER2- Highly Proliferative Breast Can...

Clinical cancer research : an official journal of the American Association for Cancer Research · 2 maart 2026

HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analyse.

The Lancet. Oncology · 2025-08

Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonstero...

Clinical cancer research : an official journal of the American Association for Cancer Research · 1 mei 2025

Imlunestrant als preoperatieve orale SERD bij ER-positief mammacarcinoom: window-studie

Clinical cancer research : an official journal of the American Association for Cancer Research · 2 december 2024

Giredestrant bij ER-positief mammacarcinoom: fase III persevERA-AI

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 juni 2024

CCNE1 en PLK1 als mediators van palbociclib-resistentie bij HR+/HER2- mammacarcinoom

Clinical cancer research : an official journal of the American Association for Cancer Research · 14 april 2023

OS met palbociclib plus endocriene therapie versus capecitabine bij mammacarcinoom: Young-PEARL update

European journal of cancer (Oxford, England : 1990) · 2022-06

QoL met palbociclib plus endocriene therapie versus capecitabine bij mammacarcinoom

European journal of cancer (Oxford, England : 1990) · 2021-10

Totale overleving met ribociclib plus fulvestrant bij gevorderd mammacarcinoom: MONALEESA-3 OS

The New England journal of medicine · 6 februari 2020

Adjuvant capecitabine na neo/adjuvante chemotherapie bij mammacarcinoom: GEICAM/CIBOMA fase III

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 januari 2020

Ribociclib plus fulvestrant bij HR-positief gevorderd mammacarcinoom: MONALEESA-3 fase III

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 augustus 2018

Chemotherapie bij geïsoleerd locoregionaal recidief mammacarcinoom naar ER-status: CALOR definitieve analyse

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 10 april 2018

PAM50-gebaseerde chemo-endocriene score bij HR-positief mammacarcinoom met intermediair recidiefrisico

Clinical cancer research : an official journal of the American Association for Cancer Research · 15 juni 2017